Trial · NCT02299414
Results by group74
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 74
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Composite Adverse Perinatal Outcome | Anti-hypertensive Therapy to Goal <140/90 mmHg | Composite Primary Outcome | 353 | Participants | |
| Composite Adverse Perinatal Outcome | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | Composite Primary Outcome | 427 | Participants | |
| Composite Adverse Perinatal Outcome | Anti-hypertensive Therapy to Goal <140/90 mmHg | Preeclampsia with Severe Features | 272 | Participants | |
| Composite Adverse Perinatal Outcome | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | Preeclampsia with Severe Features | 336 | Participants | |
| Composite Adverse Perinatal Outcome | Anti-hypertensive Therapy to Goal <140/90 mmHg | Indicated Preterm Birth <35 weeks | 143 | Participants | |
| Composite Adverse Perinatal Outcome | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | Indicated Preterm Birth <35 weeks | 193 | Participants | |
| Composite Adverse Perinatal Outcome | Anti-hypertensive Therapy to Goal <140/90 mmHg | Placental Abruption | 20 | Participants | |
| Composite Adverse Perinatal Outcome | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | Placental Abruption | 22 | Participants | |
| Composite Adverse Perinatal Outcome | Anti-hypertensive Therapy to Goal <140/90 mmHg | Fetal or Neonatal Death <28 days | 41 | Participants | |
| Composite Adverse Perinatal Outcome | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | Fetal or Neonatal Death <28 days | 50 | Participants | |
| Small for Gestational Age (Safety) | Anti-hypertensive Therapy to Goal <140/90 mmHg | 128 | Participants | ||
| Small for Gestational Age (Safety) | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | 117 | Participants | ||
| Composite of Maternal Death or Severe Cardiovascular Morbidity | Anti-hypertensive Therapy to Goal <140/90 mmHg | 25 | Participants | ||
| Composite of Maternal Death or Severe Cardiovascular Morbidity | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | 33 | Participants | ||
| Severe Maternal Hypertension + Components of the Primary Composite Endpoint | Anti-hypertensive Therapy to Goal <140/90 mmHg | 529 | Participants | ||
| Severe Maternal Hypertension + Components of the Primary Composite Endpoint | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | 631 | Participants | ||
| Preterm Birth and Indicated Preterm Birth (<37 Weeks) | Anti-hypertensive Therapy to Goal <140/90 mmHg | 332 | Participants | ||
| Preterm Birth and Indicated Preterm Birth (<37 Weeks) | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | 377 | Participants | ||
| Composite of Severe Neonatal Morbidities | Anti-hypertensive Therapy to Goal <140/90 mmHg | 24 | Participants | ||
| Composite of Severe Neonatal Morbidities | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | 31 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02299414/results